Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study

Introduction: Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe COVID-19 in at-risk outpatients. However, data on their use in hospitalized patients, particularly in elderly or immunocompromised hosts, are lacking. Methods: All consecutive patients hospitalized with COVID-19 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavaro, Davide Fiore, Diella, Lucia, Belati, Alessandra, Metrangolo, Giuliana, De Santis, Laura, Spada, Vito, Camporeale, Michele, Dargenio, Angelo, Brindicci, Gaetano, Balena, Flavia, Fiordelisi, Deborah, Signorile, Fabio, Loseto, Giacomo, Pasciolla, Crescenza, Minoia, Carla, Attolico, Immacolata, Perrone, Tommasina, Simone, Simona, Rendina, Maria, Giovine, Nicoletta, Di Gennaro, Francesco, Musto, Pellegrino, Guarini, Attilio, Di Leo, Alfredo, Gesualdo, Loreto, Dell’Aera, Maria, Saracino, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222024/
https://www.ncbi.nlm.nih.gov/pubmed/37243285
http://dx.doi.org/10.3390/v15051199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222024/
https://www.ncbi.nlm.nih.gov/pubmed/37243285
http://dx.doi.org/10.3390/v15051199

Ejemplares similares